Synergy between 3′-azido-3′-deoxythymidine and paclitaxel in human pharynx FaDu cells

Pharmaceutical Research

Volumn 20, Issue 7, 2003, Pages 957-961

  Johnston, Jeffrey S ^a   Johnson, Andrew ^a   Gan, Yuebo ^a   Wientjes, M Guillaume ^a,b   Au, Jessie L S ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

AZT; Paclitaxel; Synergy; Telomerase; Telomere

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL; TELOMERASE; ZIDOVUDINE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; LOW DRUG DOSE; METASTASIS INHIBITION; PHARYNX; PRIORITY JOURNAL; TARGET CELL DESTRUCTION; TELOMERE; DOSE RESPONSE; DRUG COMBINATION; METHODOLOGY; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; PACLITAXEL; PHARYNX; ZIDOVUDINE;

EID: 0038537338     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024431218327     Document Type: Article

References (30)

1. Y. Mo, Y. Gan, S. Song, J. Johnston, X. Xiao, M. G. Wientjes, and J. L.-S. Au. Simultaneous targetting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res. 63:579-585 (2003).
2. V. A. Zakian. Telomeres: beginning to understand the end. Science 270:1601-1607 (1995).
3. W. Fu, J. G. Begley, M. W. Killen, and M. P. Mattson. Antiapoptotic role of telomerase in pheochromocytoma cells. J. Biol. Chem. 274:7264-7271 (1999).
4. V. Urquidi, D. Tarin, and S. Goodison. Role of telomerase in cell senescence and oncogenesis. Annu. Rev. Med. 51:65-79 (2000).
5. C. I. Nugent, G. Bosco, L. O. Ross, S. K. Evans, A. P. Salinger, J. K. Moore, J. E. Haber, and V. Lundblad. Telomere maintenance is dependent on activities required for end repair of double-strand breaks. Curr. Biol. 8:657-660 (1998).
6. T. Ishikawa, M. Kamiyama, H. Hisatomi, Y. Ichikawa, N. Momiyama, Y. Hamaguchi, S. Hasegawa, T. Narita, and H. Shimada. Telomerase enzyme activity and RNA expression in adriamycin-resistant human breast carcinoma MCF-7 cells. Cancer Lett. 141:187-194 (1999).
7. N. W. Kim, M. A. Piatyszek, K. R. Prowse, C. B. Harley, M. D. West, P. L. Ho, G. M. Coviello, W. E. Wright, S. L. Weinrich, and J. W. Shay. Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015 (1994).
8. J. Feng, W. D. Funk, S. S. Wang, S. L. Weinrich, A. A. Avilion, C. P. Chiu, R. R. Adams, E. Chang, R. C. Allsopp, and J. Yu. The RNA component of human telomerase. Science 269:1236-1241 (1995).
9. T. M. Bryan, A. Englezou, L. Dalla-Pozza, M. A. Dunham, and R. R. Reddel. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nature Med. 3:1271-1274 (1997).
10. C. Strahl and E. H. Blackburn. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol. Cell. Biol. 16:53-65 (1996).
11. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. Bokesch, S. Kenney, and M. R. Boyd. New eolorimetrie eytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1107-1112 (1990).
12. M. C. Berenbaum. What is synergy? Pharmacol. Rev. 41:93-141 (1989).
13. T. C. Chou and P. Talalay. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55 (1984).
14. W. C. Hahn, S. A. Stewart, M. W. Brooks, S. G. York, E. Eaton, A. Kurachi, R. L. Beijersbergen, J. H. Knoll, M. Meyerson, and R. A. Weinberg, Inhibition of telomerase limits the growth of human cancer cells. Nature Med. 5:1164-1170 (1999).
15. Y. Kondo, S. Kondo, Y. Tanaka, T. Haqqi, B. P. Barna, and J. K. Cowell. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene 16:2243-2248 (1998).
16. B. Herbert, A. E. Pitts, S. I. Baker, S. E. Hamilton, W. E. Wright, J. W. Shay, and D. R. Corey. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. USA 96:14276-14281 (1999).
17. S. E. Holt, V. V. Glinsky, A. B. Ivanova, and G. V. Glinsky. Resistance to apoptosis in human cells conferred by telomerase function and telomere stability. Mol. Carcinogen. 25:241-248 (1999).
18. X. Zhang, V. Mar, W. Zhou, L. Harrington, and M. O. Robinson. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 13:2388-2399 (1999).
19. W. Fu, J. G. Begley, M. W. Killen, and M. P. Mattson. Antiapoptotic role of telomerase in pheochromocytoma cells. J. Biol. Chem. 274:7264-7271 (1999).
20. S. Kondo, Y. Tanaka, Y. Kondo, M. Hitomi, G. H. Barnett, Y. Ishizaka, J. Liu, T. Haqqi, A. Nishiyama, B. Villeponteau, J. K. Cowell, and B. P. Barna. Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation. FASEB J. 12:801-811 (1998).
21. J. G. Ren, H. L. Xia, T. Just, and Y. R. Dai. Hydroxyl radicalinduced apoptosis in human tumor cells is associated with telomere shortening but not telomerase inhibition and caspase activation. FEBS Lett. 488:123-132 (2001).
22. C. Strahl and E. H. Blackburn. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol. Cell. Biol. 16:53-65 (1996).
23. S. M. Melana, J. F. Holland, and B. G. Pogo. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3′-azido-3′-deoxythymidine. Clin. Cancer Res. 4:693-696 (1998).
24. A. Mazumder, D. Cooney, R. Agbaria, M. Gupta, and Y. Pommier. Inhibition of human immunodeficiency virus type 1 integrase by 3′-azido-3′-deoxythymidylate. Proc. Natl. Acad. Sci. USA 91:5771-5775 (1994).
25. W. Lewis and M. C. Dalakas. Mitochondrial toxicity of antiviral drugs. Nature Med. 1:417-422 (1995).
26. B. Jacobsson, S. Britton, Q. He, A. Karlsson, and S. Eriksson. Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: implications for zidovudine metabolism. AIDS Res. Hum. Retroviruses 11:805-811 (1995).
27. O. A. Olivero and M. C. Pokier. Preferential incorporation of 3′-azido-2′,3′-dideoxythymidine into telomeric DNA and Z-DNA-containing regions of Chinese hamster ovary cells. Mol. Carcinogen. 8:81-88 (1993).
28. B. Chandrasekaran, T. E. Kute, and D. S. Duch. Synchronization of cells in the S phase of the cell cycle by 3′-azido-3′-deoxythymidine: implications for cell cytotoxicity. Cancer Chemother. Pharmacol. 35:489-495 (1995).
29. M. D. Mediavilla and E. J. Sanchez-Barcelo. Doses and time-dependent effects of 3′-azido-3′-deoxythymidine on T47D human breast cancer cells in vitro. Pharmacol. Toxicol. 87:138-143 (2000).
30. M. Roskrow and S. N. Wickramasinghe. Acute effects of 3′-azido-3′-deoxythymidine on the cell cycle of HL60 cells. Clin. Lab. Haematol. 12:177-184 (1990).